NVAX

Business Context and Reporting Period

Company: NOVAVAX, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2005
Business Overview: Novavax is a specialty biopharmaceutical company focused on topical drug delivery technology (MNP platform) and the development of preventive vaccines using Virus-like particle (VLP) technology. Its primary commercial product is ESTRASORB, a topical estrogen therapy for menopausal symptoms, launched in June 2004. The company also sells prenatal vitamins and other prescription pharmaceuticals.

Key Financial Metrics

Note: Working capital calculated as Current Assets ($8,304) minus Current Liabilities ($5,631).

Material Changes vs. Prior Period

• Revenue Decline: Total revenues for the six months ended June 30, 2005, decreased 47% to $3.3 million from $6.2 million in the prior year. This was driven by a 46% drop in product sales, primarily due to lower ESTRASORB sales compared to the initial launch quarter in 2004 and generic pressure on the prenatal vitamin line.
• Expense Reduction: Selling and marketing expenses decreased significantly (67% for the quarter, 29% for the six months) due to the restructuring of the sales force in March 2005 and the absence of ESTRASORB launch marketing costs incurred in 2004.
• Cost of Sales Increase: Cost of products sold increased 127% year-over-year for the six-month period. This was largely due to $2.5 million in fixed idle capacity costs at the ESTRASORB manufacturing facility, as production volumes were lower than the previous year.
• Liquidity Deterioration: Cash and cash equivalents dropped from $17.9 million at year-end 2004 to $4.4 million at June 30, 2005, reflecting a net cash burn of $13.4 million in the first half of the year.

Outlook, Risks, and Management Commentary

• Product Performance: ESTRASORB prescription trends have not met initial expectations. Management attributes this to the Women's Health Initiative study effects, competitive launches, and insufficient marketing resources. The company is actively seeking a global pharmaceutical partner to commercialize ESTRASORB.
• Future Pipeline: The company plans to file or activate two Investigational New Drug (IND) applications by the first quarter of 2006. It continues to develop VLP-based vaccines for HIV, SARS, and influenza.
• Liquidity and Capital: Management anticipates lower cash requirements for the remainder of 2005 due to sales force reductions. However, they expect to require additional capital through licensing, partnerships, or equity/debt financing to sustain operations beyond 2005. Without new financing, the company may need to delay R&D or downsize further.
• Subsequent Event: In July 2005, the company completed an offering of 4,000,000 shares at $1.00 per share, raising approximately $3.6 million in net proceeds. On a pro-forma basis, this would have increased the June 30 cash balance to approximately $8.0 million.
• Leadership Change: On August 8, 2005, Nelson M. Sims retired as President and CEO. Dr. Rahul Singhvi was elected President and CEO, and Ray Hage was elected Chief Operating Officer.
• Legal Contingency: The company is defending a lawsuit from a former director regarding stock option termination. No liability is accrued, but an unfavorable outcome could materially impact results.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $4.4 million cash balance (plus $3.6 million subsequent proceeds) to fund operations through 2005 and into 2006 given the high burn rate.
• ESTRASORB Partnership: Monitor progress in securing a global pharmaceutical partner, as internal commercialization has underperformed.
• Idle Capacity Costs: Assess the timeline for reducing the significant fixed idle capacity costs ($2.5 million in H1 2005) associated with the manufacturing facility.
• Debt Obligations: Review the terms of the $35 million convertible notes and the impact of interest expense on future liquidity.
• Regulatory Milestones: Track the filing of the two planned IND applications expected in Q1 2006.